Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.39)
# 1,281
Out of 5,118 analysts
219
Total ratings
38.3%
Success rate
11.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTVT vTv Therapeutics | Reiterated: Buy | $60 | $21.03 | +185.31% | 3 | Oct 21, 2026 | |
| IMMX Immix Biopharma | Reiterated: Buy | $24 | $8.06 | +197.77% | 4 | Oct 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $12 | $2.39 | +403.14% | 48 | Oct 2, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $85 → $145 | $99.30 | +46.02% | 13 | Sep 28, 2026 | |
| SRZN Surrozen | Rated: Buy | $46 → $54 | $31.00 | +74.19% | 9 | Sep 26, 2026 | |
| ENTX Entera Bio | Initiated Coverage: Buy | $10 | $3.14 | +218.47% | 1 | Sep 23, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $104 | $20.35 | +411.06% | 14 | Sep 8, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $17 | $6.72 | +152.98% | 5 | Sep 3, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $5 | $0.7386 | +576.96% | 13 | Aug 28, 2026 | |
| SLGL Sol-Gel Technologies | Rated: Buy | $184 → $195 | $61.01 | +219.62% | 4 | Aug 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 → $63 | $25.31 | +148.91% | 13 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $91 → $121 | $51.35 | +135.64% | 8 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $41 | $7.49 | +447.40% | 10 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $68.60 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $15.60 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $2.39 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $0.3602 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $29.87 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $3.80 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €3.40 | n/a | 8 | Jun 16, 2020 |
vTv Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $60
Current: $21.03
Upside: +185.31%
Immix Biopharma
Oct 3, 2026
Reiterated: Buy
Price Target: $24
Current: $8.06
Upside: +197.77%
Rocket Pharmaceuticals
Oct 2, 2026
Reiterated: Buy
Price Target: $12
Current: $2.39
Upside: +403.14%
Kodiak Sciences
Sep 28, 2026
Reiterated: Buy
Price Target: $85 → $145
Current: $99.30
Upside: +46.02%
Surrozen
Sep 26, 2026
Rated: Buy
Price Target: $46 → $54
Current: $31.00
Upside: +74.19%
Entera Bio
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.14
Upside: +218.47%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $104
Current: $20.35
Upside: +411.06%
Achieve Life Sciences
Sep 3, 2026
Reiterated: Buy
Price Target: $17
Current: $6.72
Upside: +152.98%
iBio, Inc.
Aug 28, 2026
Reiterated: Buy
Price Target: $5
Current: $0.7386
Upside: +576.96%
Sol-Gel Technologies
Aug 22, 2026
Rated: Buy
Price Target: $184 → $195
Current: $61.01
Upside: +219.62%
Aug 11, 2026
Reiterated: Buy
Price Target: $65 → $63
Current: $25.31
Upside: +148.91%
Aug 8, 2026
Rated: Buy
Price Target: $91 → $121
Current: $51.35
Upside: +135.64%
Aug 8, 2026
Reiterated: Buy
Price Target: $45 → $41
Current: $7.49
Upside: +447.40%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $68.60
Upside: n/a
Nov 11, 2023
Reiterated: Buy
Price Target: $6
Current: $15.60
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $2.39
Upside: n/a
Mar 9, 2023
Reiterated: Buy
Price Target: $17 → $16
Current: $0.3602
Upside: n/a
Dec 11, 2022
Reiterated: Buy
Price Target: $39
Current: $29.87
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $27 → $25
Current: $3.80
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €3.40
Upside: n/a